Our previous reports showed that blocking the cyclic AMP-responsive element (CRE) site between CREB and targeted genes (Bcl-2 and cyclins), abrogated the anti-tumor drug-induced apoptosis and cell proliferation [15, 16]. Here, CREB1 is linked to neoplasm.